(Q77834533)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11918688%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

title

Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11918688%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

author name string

Jie-Hui Li

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11918688%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

Dalia Rosen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11918688%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

Paul Sondel

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11918688%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

Gideon Berke

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11918688%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

publication date

1 March 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11918688%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11918688%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

volume

105

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11918688%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11918688%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

page(s)

267-277

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11918688%20AND%20SRC:MED&resulttype=core&format=json

The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects

8 December 2019

cites work

1 reference

12 December 2020

Use of a flow cytometric assay to quantitate apoptosis in human lymphocytes.

1 reference

12 December 2020

1 reference

12 December 2020

The role of the Fas lytic pathway in a perforin-less CTL hybridoma.

1 reference

12 December 2020

Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes

1 reference

12 December 2020

Stimulation of CD95 (Fas) blocks T lymphocyte calcium channels through sphingomyelinase and sphingolipids.

1 reference

12 December 2020

Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x(L)

1 reference

12 December 2020

A role for CD95 ligand in preventing graft rejection

1 reference

12 December 2020

Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege

1 reference

12 December 2020

Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo.

1 reference

12 December 2020

Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape

1 reference

12 December 2020

Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?

1 reference

12 December 2020

Antitumor effect of locally produced CD95 ligand

1 reference

12 December 2020

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand

1 reference

12 December 2020

Apoptosis by death factor

1 reference

12 December 2020

Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

1 reference

12 December 2020

Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants

1 reference

12 December 2020

Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand.

1 reference

12 December 2020

Gene transfer of Fas ligand induces tumor regression in vivo

1 reference

12 December 2020

Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing

1 reference

12 December 2020

The regulation of CD95 ligand expression and function in CTL

1 reference

12 December 2020

Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells

1 reference

12 December 2020

Prevention of constitutive TNF receptor 1 signaling by silencer of death domains

1 reference

12 December 2020

The Fas counterattack: cancer as a site of immune privilege

1 reference

12 December 2020

Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition

1 reference

12 December 2020

Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells

1 reference

12 December 2020

Tumor counterattack--concept and reality

1 reference

12 December 2020

Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape

1 reference

12 December 2020

Countering the 'counterattack' hypothesis.

1 reference

12 December 2020

Immune privilege or inflammation? Insights into the Fas ligand enigma

1 reference

12 December 2020

A safe packaging line for gene transfer: separating viral genes on two different plasmids

1 reference

12 December 2020

Monoclonal antibody-mediated tumor regression by induction of apoptosis.

1 reference

12 December 2020

Improved retroviral vectors for gene transfer and expression

1 reference

12 December 2020

The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis

1 reference

12 December 2020

Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity

1 reference

12 December 2020

Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand

1 reference

12 December 2020